This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Global Neurostimulation Industry

8. NEUROSTIMULATION DEVICE APPROVALS II-29

SPR™ Therapeutics' SMARTPATCH™ Neurostimulation System

Obtains FDA's IDE Approval II-29

Bioness Receives FDA Clearance for Use of Smaller Leg Cuff

with L300 Foot Drop System II-29

Imthera Medical's AURA6000 Awarded CE Mark for Sleep Apnea

Therapy II-29

Neuronetics' Magnetic Brain Stimulation Device Receives CE

Approval II-30

St. Jude Medical's Eon Mini Stimulator Obtains European CE

Mark Approval II-30

Boston Scientific's Precision Plus SCS Wins FDA Approval for

Limb Pain II-30

Boston Scientific's Infinion™ 16 Percutaneous Lead Obtains CE

Approval II-30

NeuroSigma Obtains CE Approval for Monarch Nerve Stimulation

System II-31

Neurotech's ADNS-300 Neurostimulation Device Obtains CE Mark

Approval II-31

Bioness Bags FDA Approval for NESS L300 Plus, for Managing

Thigh Weakness II-31

Bioness Obtains CE Mark Approval and FDA Clearance For NESS

H200 Hand Rehabilitation System II-31

Boston Scientific's Clik Anchor Obtains FDA Approval II-32

Medtronic's AdaptiveStim RestoreSensor Lands US FDA Approval II-32

Synapse Biomedical Obtains FDA Approval for NeuRx Diaphragm

Pacing System II-32

St Jude Medical's Genesis System Secures CE Mark Approval II-32

St. Jude Receives Approval for Neurostimulation System from

Japanese MHLW II-33

St. Jude Secures European CE Mark Approval for Epiducer™ Lead

Delivery System II-33

St. Jude Medical Obtains TGA Approval for Brio™ DBS System II-33

Boston Scientific Secures FDA Approval for D4 and W4 SCS Lead

Splitters II-33

St. Jude Medical Receives Approval for Penta Neurostimulation

Lead from FDA II-34

St. Jude Receives European CE Mark Approval for LibraXP™ and

Libra® Deep Brain Stimulation Systems II-34

Medtronic Receives FDA Approval for Activa PC and Activa RC

DBS Devices II-34

Medtronic Receives FDA Approval for Reclaim™ Deep Brain

Stimulation Therapy II-34

St. Jude Receives European CE Mark Approval for Genesis®

Neurostimulation System II-35

St. Jude Eon Mini™ Neurostimulator Receives Australian

Therapeutic Goods Administration Approval II-35

Medtronic Receives FDA Approval for Activa® RC, Activa PC DBS

3 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs